Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 17004 participants.

Also called NCT05030428

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 17,004 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05030428
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Greece, Hungary, Iceland, India, Israel, Italy, Japan, Kenya, Latvia, Lithuania, Malaysia, Mauritius, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05030428. Randomized; double masking; primary purpose treatment. Start 2021-11-23 (actual); primary completion 2027-05-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Acronym
VICTORION-2P
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Inclisiran sodium 300 mg
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05030428
Content hash
1ed419ef8e4656e54aebf474ea64745b0be336dc82f822923e52c8aa82fb5ad0